News, trends, and stories from the synthetic biology industry
Hi ,
When we hosted the first SynBioBeta in June of 2012, 150 people showed up. Amongst those people were two of the three founders of Zymergen: Zach Serber and Jed Dean. Along with Josh Hoffman, they went on to found Zymergen, which yesterday announced plans for its $100 million IPO. A big congratulations to the whole team for the progress that's been made over the last nine years.
Zach Serber, Jed Dean and Josh Hoffman.
This week, we bring you an in-depth look on the state of monoclonal antibodies and a key pending FDA decision, Synthetic Biology Clubhouse breaking news, the latest experts speakers at our Biopharma event and more:
Join us TODAY at 8 am PST for the Synthetic Biology Breaking News conversation on Clubhouse. Speakers include:
Eduardo Abeliuk, CEO of TeselaGen, who recently announced a partnership with Berkeley Lab’s Advanced Biofuels and Bioproducts Process Development Unit to advance fermentation processing for next-generation renewable bioproducts.
Our special Biopharma event just keeps getting better—check out our latest speaker lineup! You still have a few days to save up to $300 before our Early Bird offer is gone. Get your tickets now!
SynBioBeta: In-Depth
Can Monoclonal Antibodies Cure Alzheimer’s? How are synthetic antibodies changing treatment options for
Alzheimer’s disease, one of the leading causes of death in the world? The FDA is expected to decide in the next few months whether or not to approve the first monoclonal antibody for Alzheimer’s treatment.
John Cumbers for Forbes
The Latest Quantified Self Trend: Whole-Body MRI A new, advanced resolution whole body MRI by
diagnostics company Prenuvo revealed surprising results for John Cumbers. Should whole body MRIs become routine? What is the quantified self movement and how could greater access to personalized health data change our relationship to healthcare?
Congrats to Helge Bastian (who many of you know from our events at SynBioBeta), he is the CEO of M2GEN, which has announced the closing of their capital raise as well as the signing of a new 5-year agreement with Merck to accelerate the delivery of personalized cancer therapies.
